HomeCompareGILD vs ROL

GILD vs ROL: Dividend Comparison 2026

GILD yields 2.34% · ROL yields 1.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ROL wins by $14.14M in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
ROL
ROL
● Live price
1.38%
Share price
$53.04
Annual div
$0.73
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.17M
Annual income
$12,435,164.79
Full ROL calculator →

Portfolio growth — GILD vs ROL

📍 ROL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDROL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + ROL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
ROL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
ROL
Annual income on $10K today (after 15% tax)
$116.99/yr
After 10yr DRIP, annual income (after tax)
$10,569,890.07/yr
At 15% tax rate, ROL beats the other by $10,568,517.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + ROL for your $10,000?

GILD: 50%ROL: 50%
100% ROL50/50100% GILD
Portfolio after 10yr
$7.10M
Annual income
$6,218,389.84/yr
Blended yield
87.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
ROL
Analyst Ratings
8
Buy
9
Hold
Consensus: Hold
Price Target
$64.00
+20.7% upside vs current
Range: $52.00 — $72.00
Altman Z
10.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
ROL buys
0
No recent congressional trades found for GILD or ROL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDROL
Forward yield2.34%1.38%
Annual dividend / share$3.19$0.73
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%100%
Portfolio after 10y$29.1K$14.17M
Annual income after 10y$1,614.90$12,435,164.79
Total dividends collected$7.6K$14.01M
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyHold
Analyst price target$158.71$64.00

Year-by-year: GILD vs ROL ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrROL PortfolioROL Income/yrGap
1← crossover$10,974$274.45$10,975$275.26$1.00ROL
2$12,073$330.19$12,308$564.69$235.00ROL
3$13,316$398.20$14,353$1,183.69$1.0KROL
4$14,730$481.49$17,938$2,580.15$3.2KROL
5$16,345$583.87$25,221$6,027.23$8.9KROL
6$18,199$710.26$42,827$15,839.73$24.6KROL
7$20,340$866.96$96,098$50,273.53$75.8KROL
8$22,826$1,062.22$313,681$210,856.41$290.9KROL
9$25,731$1,306.80$1,622,132$1,286,493.33$1.60MROL
10$29,147$1,614.90$14,170,846$12,435,164.79$14.14MROL

GILD vs ROL: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

ROLIndustrials

Rollins, Inc., through its subsidiaries, provides pest and wildlife control services to residential and commercial customers in the United States and internationally. The company offers pest control services to residential properties protecting from common pests, including rodents, insects, and wildlife. It also provides workplace pest control solutions for customers across various end markets, such as healthcare, foodservice, and logistics. In addition, the company offers traditional and baiting termite protection, as well as ancillary services. It serves clients directly, as well as through franchisee operations. Rollins, Inc. was incorporated in 1948 and is headquartered in Atlanta, Georgia.

Full ROL Calculator →
📬

Get this GILD vs ROL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.